CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

$4.9M

Market Cap • 11/18/2024

2017

(7 years)
Founded

2019

(5 years ago)
IPO

NASDAQ

Listing Exchange
Flag of US

Houston

Headquarters • Texas